bufalin has been researched along with Adenocarcinoma of Lung in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, S; Li, F; Li, L; Liu, F; Lu, X; Shi, S; Tian, X; Xiang, L; Zang, H; Zhao, S | 1 |
| Li, E; Liu, Y; Ma, G; Sun, H; Wang, Z; Zhu, Z | 1 |
2 other study(ies) available for bufalin and Adenocarcinoma of Lung
| Article | Year |
|---|---|
Molecular and metabolic mechanisms of bufalin against lung adenocarcinoma: New and comprehensive evidences from network pharmacology, metabolomics and molecular biology experiment.
Topics: Adenocarcinoma of Lung; Animals; Drugs, Chinese Herbal; Lung Neoplasms; Mice; Mice, Nude; Molecular Biology; Molecular Docking Simulation; Network Pharmacology; Phosphatidylinositol 3-Kinases | 2023 |
Bufalin induces lung cancer cell apoptosis via the inhibition of PI3K/Akt pathway.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Bufanolides; Cell Proliferation; Down-Regulation; Humans; Lung Neoplasms; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Signal Transduction; Tumor Cells, Cultured | 2012 |